Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Calcified Tissue International
Published in: Calcified Tissue International 3/2021

Open Access 01-09-2021 | Osteoarthrosis | Review

Prospects for Therapies in Osteoarthritis

Authors: Asim Ghouri, Philip G. Conaghan

Published in: Calcified Tissue International | Issue 3/2021

Login to get access

Abstract

Osteoarthritis (OA) is a chronic, debilitating disease affecting millions of people worldwide. Management of OA involves pharmacological and non-pharmacological approaches. Conventional pharmacological treatments have limited efficacy and are associated with a number of side-effects, restricting the number of patients who can use them. New pharmacological therapies for managing OA are required and a number have been developed targeting different tissues in OA: bone and cartilage, synovium and nerves. However, there has been overall limited success. Disease-modifying osteoarthritis drugs (DMOADs) are a putative class of therapies aimed at improving OA structural pathologies and consequent symptoms. Recent DMOAD studies have demonstrated some promising therapies but also provided new considerations for future trials.
Literature
1.
C Global Burden of Disease Study (2015) Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet (London, England) 386(9995):743–800CrossRef
2.
Neogi T, Zhang Y (2013) Epidemiology of osteoarthritis. Rheum Dis Clin N Am 39(1):1–19CrossRef
3.
Salmon JH et al (2016) Economic impact of lower-limb osteoarthritis worldwide: a systematic review of cost-of-illness studies. Osteoarthr Cartil 24(9):1500–1508CrossRef
4.
5.
Yusuf E et al (2011) Do knee abnormalities visualised on MRI explain knee pain in knee osteoarthritis? A systematic review. Ann Rheum Dis 70(1):60PubMedCrossRef
6.
Zhang W et al (2010) OARSI recommendations for the management of hip and knee osteoarthritis: part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthr Cartil 18(4):476–499CrossRef
7.
Sharma AR et al (2013) Interplay between cartilage and subchondral bone contributing to pathogenesis of osteoarthritis. Int J Mol Sci 14(10):19805–19830PubMedPubMedCentralCrossRef
8.
Blumenkrantz G et al (2004) A pilot, two-year longitudinal study of the interrelationship between trabecular bone and articular cartilage in the osteoarthritic knee. Osteoarthr Cartil 12(12):997–1005CrossRef
9.
Karvonen RL et al (1998) Periarticular osteoporosis in osteoarthritis of the knee. J Rheumatol 25(11):2187–2194PubMed
10.
Vaysbrot EE et al (2018) Are bisphosphonates efficacious in knee osteoarthritis? A meta-analysis of randomized controlled trials. Osteoarthr Cartil 26(2):154–164CrossRef
11.
Spector TD et al (2005) Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial [ISRCTN01928173]. Arthritis Res Ther 7(3):R625–R633PubMedPubMedCentralCrossRef
12.
Bingham CO 3rd et al (2006) Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study. Arthritis Rheum 54(11):3494–3507PubMedCrossRef
13.
Laslett LL et al (2012) Zoledronic acid reduces knee pain and bone marrow lesions over 1 year: a randomised controlled trial. Ann Rheum Dis 71(8):1322PubMedCrossRef
14.
Rossini M et al (2015) Effects of intra-articular clodronate in the treatment of knee osteoarthritis: results of a double-blind, randomized placebo-controlled trial. Rheumatol Int 35(2):255–263PubMedCrossRef
15.
Varenna M et al (2015) Intravenous neridronate in the treatment of acute painful knee osteoarthritis: a randomized controlled study. Rheumatology (Oxford) 54(10):1826–1832CrossRef
16.
Felson DT et al (2001) The association of bone marrow lesions with pain in knee osteoarthritis. Ann Intern Med 134(7):541–549PubMedCrossRef
17.
Zhai G et al (2006) Correlates of knee pain in older adults: Tasmanian older adult cohort study. Arthritis Care Res 55(2):264–271CrossRef
18.
Felson DT et al (2003) Bone marrow edema and its relation to progression of knee osteoarthritis. Ann Intern Med 139(5_Part_1):330–336PubMedCrossRef
19.
Castañeda S et al (2012) Subchondral bone as a key target for osteoarthritis treatment. Biochem Pharmacol 83(3):315–323PubMedCrossRef
20.
Cai G et al (2018) OP0016 A multicentre randomised controlled trial of zoledronic acid for osteoarthritis of the knee with bone marrow lesions. Ann Rheum Dis 77(Suppl 2):57
21.
Reginster J-Y et al (2013) Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial. Ann Rheum Dis 72(2):179PubMedCrossRef
22.
23.
Moore EE et al (2005) Fibroblast growth factor-18 stimulates chondrogenesis and cartilage repair in a rat model of injury-induced osteoarthritis. Osteoarthr Cartil 13(7):623–631CrossRef
24.
25.
Davidson D et al (2005) Fibroblast growth factor (FGF) 18 signals through FGF receptor 3 to promote chondrogenesis. J Biol Chem 280(21):20509–20515PubMedCrossRef
26.
Lohmander LS et al (2014) Intraarticular sprifermin (recombinant human fibroblast growth factor 18) in knee osteoarthritis: a randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol 66(7):1820–1831PubMedCrossRef
27.
Hochberg MC et al (2019) Effect of intra-articular sprifermin vs placebo on femorotibial joint cartilage thickness in patients with osteoarthritis: the FORWARD Randomized Clinical Trial. JAMA 322(14):1360–1370PubMedPubMedCentralCrossRef
28.
Hochberg M et al (2018) OP0059 Efficacy and safety of intra-articular sprifermin in symptomatic radiographic knee osteoarthritis: pre-specified analysis of 3-year data from a 5-year randomised, placebo-controlled, phase ii study. Ann Rheum Dis 77(Suppl 2):80–81
29.
Gühring H et al (2019) OP0010 cartilage thickness modification with sprifermin in knee osteoarthritis patients translates into symptomatic improvement over placebo in patients at risk of further structural and symptomatic progression: post-hoc analysis of the phase II forward trial. Ann Rheum Dis 78(Suppl 2):70
30.
Deshmukh V et al (2018) A small-molecule inhibitor of the Wnt pathway (SM04690) as a potential disease modifying agent for the treatment of osteoarthritis of the knee. Osteoarthr Cartil 26(1):18–27CrossRef
31.
32.
Deshmukh V et al (2019) Modulation of the Wnt pathway through inhibition of CLK2 and DYRK1A by lorecivivint as a novel, potentially disease-modifying approach for knee osteoarthritis treatment. Osteoarthr Cartil 27(9):1347–1360CrossRef
33.
Kennedy S et al (2018) OP0061 Treatment of knee osteoarthritis with sm04690 improved womac a1 ‘pain on walking’—results from a 52 week, randomised, double-blind, placebo-controlled, phase 2 study of a novel, intra-articular, wnt pathway inhibitor. Ann Rheum Dis 77(Suppl 2):81–82
34.
Yazici Y et al (2018) Radiographic outcomes were concordant with outcome measures in rheumatology-osteoarthritis research society international (OMERACT-OARSI) strict response: post-hoc analysis from a phase 2 study of a WNT pathway inhibitor, SM04690, for knee osteoarthritis treatment. Osteoarthr Cartil 26:S244–S245CrossRef
35.
Yazici Y et al (2019) THU0458 Efficacy and safety from a phase 2B trial of SM04690, a novel intra-articular wnt pathway inhibitor for the treatment of osteoarthritis of the knee. Ann Rheum Dis 78(Suppl 2):519
36.
37.
Lindström E et al (2018) Nonclinical and clinical pharmacological characterization of the potent and selective cathepsin K inhibitor MIV-711. J Transl Med 16(1):125PubMedPubMedCentralCrossRef
38.
McClung MR et al (2019) Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study. Lancet Diabetes Endocrinol 7(12):899–911PubMedCrossRef
39.
40.
Bowes MA et al (2015) A novel method for bone area measurement provides new insights into osteoarthritis and its progression. Ann Rheum Dis 74(3):519PubMedCrossRef
41.
Conaghan PG et al (2018) Six months’ treatment with MIV-711, a novel Cathepsin K inhibitor induces osteoarthritis structure modification: results from a randomized double-blind placebo-controlled phase IIA trial. Osteoarthr Cartil 26:S25–S26CrossRef
42.
Szallasi A et al (2007) The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept. Nat Rev Drug Discov 6:357PubMedCrossRef
43.
44.
Altman RD et al (1994) Capsaicin cream 0.025% as monotherapy for osteoarthritis: a double-blind study. Semin Arthritis Rheum 23(6):25–33CrossRef
45.
46.
Zhang WY, Li-Wan-Po A (1994) The effectiveness of topically applied capsaicin. A meta-analysis. Eur J Clin Pharmacol 46:517–522PubMedCrossRef
47.
Kosuwon W et al (2010) Efficacy of symptomatic control of knee osteoarthritis with 0.0125% of capsaicin versus placebo. J Med Assoc Thail 93:1188–1195
48.
Stevens RM et al (2019) Randomized, double-blind, placebo-controlled trial of intra-articular CNTX-4975 (trans-capsaicin) for pain associated with osteoarthritis of the knee. Arthritis Rheumatol 71(9):1524–1533PubMedPubMedCentralCrossRef
49.
50.
51.
Denk F, Bennett DL, McMahon SB (2017) Nerve growth factor and pain mechanisms. Annu Rev Neurosci 40(1):307–325PubMedCrossRef
52.
53.
Abdiche YN, Malashock DS, Pons J (2009) Probing the binding mechanism and affinity of tanezumab, a recombinant humanized anti-NGF monoclonal antibody, using a repertoire of biosensors. Protein Sci 17(8):1326–1335CrossRef
54.
Chen J et al (2017) Efficacy and safety of tanezumab on osteoarthritis knee and hip pains: a meta-analysis of randomized controlled trials. Pain Med 18(2):374–385PubMed
55.
Schnitzer TJ et al (2019) Effect of tanezumab on joint pain, physical function, and patient global assessment of osteoarthritis among patients with osteoarthritis of the hip or knee: a randomized clinical trialeffect of tanezumab on joint pain, physical function, and patient global assessment of osteoarthritiseffect of tanezumab on joint pain, physical function, and patient global assessment of osteoarthritis. JAMA 322(1):37–48PubMedPubMedCentralCrossRef
56.
Spierings ELH et al (2013) A phase III placebo- and oxycodone-controlled study of tanezumab in adults with osteoarthritis pain of the hip or knee. PAIN® 154(9):1603–1612CrossRef
57.
Schnitzer TJ et al (2015) Efficacy and safety of tanezumab monotherapy or combined with non-steroidal anti-inflammatory drugs in the treatment of knee or hip osteoarthritis pain. Ann Rheum Dis 74(6):1202PubMedCrossRef
58.
59.
Dakin P et al (2019) The efficacy, tolerability and joint safety of fasinumab in osteoarthritis pain: a phase IIb/III double-blind, placebo-controlled, randomized clinical trial. Arthritis Rheumatol 71(11):1824–1834PubMedPubMedCentralCrossRef
60.
Hochberg MC (2015) Serious joint-related adverse events in randomized controlled trials of anti-nerve growth factor monoclonal antibodies. Osteoarthr Cartil 23:S18–S21CrossRef
61.
Hochberg MC et al (2015) When is osteonecrosis not osteonecrosis?: Adjudication of reported serious adverse joint events in the tanezumab clinical development program. Arthritis Rheumatol 68(2):382–391CrossRef
62.
63.
64.
da Costa BR, Hari R, Jüni P (2016) Intra-articular corticosteroids for osteoarthritis of the knee. JAMA 316(24):2671–2672PubMedCrossRef
65.
66.
Bodick N et al (2015) An intra-articular, extended-release formulation of triamcinolone acetonide prolongs and amplifies analgesic effect in patients with osteoarthritis of the knee: a randomized clinical trial. J Bone Jt Surg Am 97(11):877–888CrossRef
67.
Conaghan PG et al (2018) Brief report: a phase IIb trial of a novel extended-release microsphere formulation of triamcinolone acetonide for intraarticular injection in knee osteoarthritis. Arthritis Rheumatol 70(2):204–211PubMedCrossRef
68.
Conaghan PG et al (2018) Effects of a single intra-articular injection of a microsphere formulation of triamcinolone acetonide on knee osteoarthritis pain: a double-blinded, randomized, placebo-controlled, multinational study. JBJS 100(8):666–677CrossRef
69.
Kraus VB et al (2018) Synovial and systemic pharmacokinetics (PK) of triamcinolone acetonide (TA) following intra-articular (IA) injection of an extended-release microsphere-based formulation (FX006) or standard crystalline suspension in patients with knee osteoarthritis (OA). Osteoarthr Cartil 26(1):34–42CrossRef
70.
Conaghan PG et al (2018) Triamcinolone acetonide extended-release injectable suspension (TA-ER) is associated with reduced blood glucose elevation vs. standard triamcinolone in type 2 diabetes mellitus patients with knee osteoarthritis: a randomized, blinded, parallel-group study. Osteoarthr Cartil 26:S230CrossRef
71.
Haar D et al (1993) A double-blind comparative study of hydroxychloroquine and dapsone, alone and in combination, in rheumatoid arthritis. Scand J Rheumatol 22(3):113–118PubMedCrossRef
72.
Clark P et al (1993) Hydroxychloroquine compared with placebo in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med 119(11):1067–1071PubMedCrossRef
73.
Kyburz D, Brentano F, Gay S (2006) Mode of action of hydroxychloroquine in RA—evidence of an inhibitory effect on toll-like receptor signaling. Nat Clin Pract Rheumatol 2:458PubMedCrossRef
74.
Kim HA et al (2006) The catabolic pathway mediated by Toll-like receptors in human osteoarthritic chondrocytes. Arthritis Rheum 54(7):2152–2163PubMedCrossRef
75.
76.
Keen HI et al (2008) An ultrasonographic study of osteoarthritis of the hand: synovitis and its relationship to structural pathology and symptoms. Arthritis Care Res 59(12):1756–1763CrossRef
77.
Vlychou M et al (2009) Ultrasonographic evidence of inflammation is frequent in hands of patients with erosive osteoarthritis. Osteoarthr Cartil 17(10):1283–1287CrossRef
78.
Bryant LR, des Rosier KF, Carpenter MT (1995) Hydroxychloroquine in the treatment of erosive osteoarthritis. J Rheumatol 22(8):1527–1531PubMed
79.
Punzi L et al (1996) Soluble interleukin 2 receptors and treatment with hydroxychloroquine in erosive osteoarthritis. J Rheumatol 23(8):1477–1478PubMed
80.
Kingsbury SR et al (2018) Hydroxychloroquine effectiveness in reducing symptoms of hand osteoarthritis: a randomized trial. Ann Intern Med 168(6):385–395PubMedCrossRef
81.
Lee W et al (2017) Efficacy of hydroxychloroquine in hand osteoarthritis: a randomized, double-blind, placebo-controlled trial. Arthritis Care Res 70(9):1320–1325CrossRef
82.
Wojdasiewicz P, Poniatowski LA, Szukiewicz D (2014) The role of inflammatory and anti-inflammatory cytokines in the pathogenesis of osteoarthritis. Mediat Inflamm 2014:561459CrossRef
83.
Verbruggen G et al (2012) Tumour necrosis factor blockade for the treatment of erosive osteoarthritis of the interphalangeal finger joints: a double blind, randomised trial on structure modification. Ann Rheum Dis 71(6):891PubMedCrossRef
84.
Chevalier X et al (2015) Adalimumab in patients with hand osteoarthritis refractory to analgesics and NSAIDs: a randomised, multicentre, double-blind, placebo-controlled trial. Ann Rheum Dis 74(9):1697–1705PubMedCrossRef
85.
Aitken D et al (2018) A randomised double-blind placebo-controlled crossover trial of HUMira (adalimumab) for erosive hand OsteoaRthritis—the HUMOR trial. Osteoarthr Cartil 26(7):880–887CrossRef
86.
Kloppenburg M et al (2018) Etanercept in patients with inflammatory hand osteoarthritis (EHOA): a multicentre, randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 77(12):1757PubMedCrossRef
87.
Smith MD et al (1997) Synovial membrane inflammation and cytokine production in patients with early osteoarthritis. J Rheumatol 24:365–371PubMed
88.
Furuzawa-Carballeda J, Macip-Rodriguez PM, Cabral AR (2008) Osteoarthritis and rheumatoid arthritis pannus have similar qualitative metabolic characteristics and pro-inflammatory cytokine response. Clin Exp Rheumatol 26:554–560PubMed
89.
90.
Caron JP et al (1996) Chondroprotective effect of intraarticular injections of interleukin-1 receptor antagonist in experimental osteoarthritis. Suppression of collagenase-1 expression. Arthritis Rheum 39(9):1535–1544PubMedCrossRef
91.
Pelletier J-P et al (2005) In vivo suppression of early experimental osteoarthritis by interleukin-1 receptor antagonist using gene therapy. Arthritis Rheum 40(6):1012–1019CrossRef
92.
Fernandes J et al (1999) In vivo transfer of interleukin-1 receptor antagonist gene in osteoarthritic rabbit knee joints : prevention of osteoarthritis progression. Am J Pathol 154(4):1159–1169PubMedPubMedCentralCrossRef
93.
Frisbie DD et al (2002) Treatment of experimental equine osteoarthritis by in vivo delivery of the equine interleukin-1 receptor antagonist gene. Gene Ther 9:12PubMedCrossRef
94.
Chevalier X et al (2009) Intraarticular injection of anakinra in osteoarthritis of the knee: A multicenter, randomized, double-blind, placebo-controlled study. Arthritis Care Res 61(3):344–352CrossRef
95.
Lacy SE et al (2015) Generation and characterization of ABT-981, a dual variable domain immunoglobulin (DVD-Ig(TM)) molecule that specifically and potently neutralizes both IL-1α and IL-1β. mAbs 7(3):605–619PubMedPubMedCentralCrossRef
96.
Fleischmann R et al (2018) SAT0575 Safety and efficacy of lutikizumab (ABT-981), an anti–interleukin-1 alpha/beta dual variable domain (DVD) immunoglobulin, in subjects with knee osteoarthritis: results from the randomised, double-blind, placebo-controlled, parallel-group phase 2 trial. Ann Rheum Dis 77(Suppl 2):1141
97.
Kloppenburg M et al (2017) OP0168 A phase 2a, placebo-controlled, randomized study of ABT-981, an anti-interleukin-1ALPHA and -1BETA dual variable domain immunoglobulin, to treat erosive hand osteoarthritis (EHOA). Ann Rheum Dis 76(Suppl 2):122
98.
Cheleschi S et al (2015) Possible chondroprotective effect of canakinumab: an in vitro study on human osteoarthritic chondrocytes. Cytokine 71(2):165–172PubMedCrossRef
99.
Ridker PM et al (2017) Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 377(12):1119–1131PubMedCrossRef
100.
101.
102.
Metadata
Title
Prospects for Therapies in Osteoarthritis
Authors
Asim Ghouri
Philip G. Conaghan
Publication date
01-09-2021
Publisher
Springer US
Published in
Calcified Tissue International / Issue 3/2021
Print ISSN: 0171-967X
Electronic ISSN: 1432-0827
DOI
https://doi.org/10.1007/s00223-020-00672-9

Other articles of this Issue 3/2021

Calcified Tissue International 3/2021 Go to the issue

Review

Osteoarthritis: Current Molecular Biomarkers and the Way Forward

Review

Targeting Dysregulation of Metalloproteinase Activity in Osteoarthritis

Review

The Genetic Epidemiology of Joint Shape and the Development of Osteoarthritis

Review

The Bone Cartilage Interface and Osteoarthritis

Review

“Lessons from Rare Forms of Osteoarthritis”

Review

Models of Osteoarthritis: Relevance and New Insights
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits